Table 1 Patient demographics
From: A proteo-transcriptomic map of non-alcoholic fatty liver disease signatures
Clinical feature | Discovery cohort (n = 191) | Discovery RNA-seq cohort (n = 52) | Validation cohort (n = 115) |
|---|---|---|---|
Age (years) | 55.24 ± 11.04 | 54.02 ± 13.25 | 52.32 ± 12.53 |
Sex (% female) | 38.7 | 36.5 | 44.3 |
BMI | 33.47 ± 6.67 | 31.31 ± 5.38 | 32 ± 5.82 |
T2DM (%) | 60.73 | 57.7 | 52.2 |
Platelets ×109 | 224.08 ± 67.57 | 216.1 ± 60.59 | 232.75 ± 62.86 |
Albumin (g dl−1) | 4.47 ± 0.34 | 4.47 ± 0.3 | 4.24 ± 0.37 |
AST (μ l−1) | 43.27 ± 21.80 | 42.44 ± 24.31 | 49.82 ± 31.37 |
ALT (μ l−1) | 59.70 ± 33.47 | 59.65 ± 33.03 | 72.39 ± 49.81 |
Steatosis | |||
1 | 72 | 19 | 50 |
2 | 82 | 27 | 46 |
3 | 37 | 6 | 19 |
Ballooning | |||
0 | 26 | 9 | 41 |
1 | 108 | 31 | 47 |
2 | 57 | 12 | 27 |
Lobular inflammation | |||
0 | 19 | 3 | 28 |
1 | 109 | 39 | 60 |
2 | 61 | 9 | 24 |
3 | 2 | 1 | 3 |
Brunt fibrosis | |||
0 | 30 | 11 | 22 |
1 | 56 | 14 | 29 |
2 | 26 | 7 | 33 |
3 | 56 | 12 | 19 |
4 | 23 | 8 | 12 |
